Probi secures strategic US order

Probi has secured a major order valued at MSEK 3.6 from the US self-care product
company Pharmavite. The order pertains to the dietary supplement Probi
Digestis®, which promotes gastrointestinal health. The order is based on strong
demand for Probi’s digestive health capsules in US pharmacies and retail stores.
The order consisting of a number of part shipments will be delivered during the
second and third quarter of 2014.

This is one of the largest orders ever received by Probi in the Consumer
Healthcare business area.

“Our partnership with Pharmavite has been expanded over the past year. We highly
value Pharmavite’s confidence in our products. Our assessment is that we have a
continued strong development in the North American market ahead of us,” says
Peter Nählstedt, CEO of Probi.

Pharmavite launched Probi’s digestive health capsules in the US market in 2012
and they have accounted for a significant portion of Probi’s growth in the US.
The digestive health capsules, marketed under the Nature Made®brand, are Probi’s
dietary supplement Probi Digestis® and are based on the company’s well
-documented probiotic strain Lactobacillus plantarum 299v (DSM 9843).

Pharmavite operates in the self-care market niche and has been active in the US
market for more than 40 years. The company markets and sells vitamins, minerals,
dietary supplements and health food products under well-known brands such as
Nature Made® and SOYJOY®. Pharmavite is based in Northridge, California, and is
a subsidiary of the global pharmaceutical company Otsuka Pharmaceutical.

In addition to Pharmavite, Probi has well-established partnerships with the
probiotics specialist Viva 5 Corporation and the healthcare product company
Wakunaga, as well as NextFoods in the Functional Food segment.

FOR MORE INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel: +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Bjärum, VP Marketing & Sales, tel +46 46 286 89 67 or mobile +46 705 38
88 64, e-mail: niklas.bjarum@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops
effective and well-documented probiotics. Through its research, Probi has
created a strong product portfolio in the gastrointestinal health and immune
system areas. The products are available to consumers in more than 30 countries
worldwide.  The customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments. Probi had
sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm,
Small-cap. Probi has approximately 4,000 shareholders. Read more on
www.probi.se.